CGTN: What Are Generations of Chinese Communists Striving For?
27.2.2021 18:36:00 EET | Business Wire | Press release
The Communist Party of China (CPC), the ruling party of the world's most populous nation and the second largest economy, is turning 100 this year. What has been motivating the CPC to fight against one challenge after another over the past century?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210227005021/en/
"The original aspiration and the mission of Chinese Communists is to seek happiness for the Chinese people and rejuvenation for the Chinese nation," General Secretary Xi Jinping of the CPC Central Committee said in his report to the 19th CPC National Congress in October 2017.
"This founding aspiration, this mission, is what inspires the Chinese Communists to advance," Xi said.
Self-discipline, selflessness
In March 2018, Xi, also the Chinese president, further explained the cause pursued by the CPC with a quote from an ancient poem: "A virtuous person is as sharp-sighted as a clear mirror hanging high, a selfless person is just like a lit candle giving all of its light to others."
He made the quotation at a symposium to commemorate the 120th birthday of late Premier Zhou Enlai (1898-1976), who joined the CPC in 1921, the year when the Party was founded.
"The lofty character of comrade Zhou Enlai, who selflessly pursued a just cause for the common good throughout his life, vividly reflects the traditional virtue of the Chinese nation and good moral qualities of the Chinese Communists, and will forever earn the respect of future generations," said Xi.
The comments "not only aimed to remember the noble character of Zhou who was self-disciplined, upright, honest and selfless, but also to encourage today's Communists to stay true to their original aspirations of the Party and shoulder their responsibilities," said Meng Man, a history professor at Minzu University of China.
New challenges, same aspiration
The number of the CPC members has exceeded 90 million, and China has become a much stronger nation than 100 years ago and the early decades of the People's Republic of China, but the aspiration of the Chinese Communists remains unchanged.
"To meet the people's desire for a happy life is our mission," Xi said when meeting the press after being elected as general secretary of the CPC Central Committee in November 2012.
Three years later, the communique of the fifth plenary session of the 18th CPC Central Committee underscored a people-centered development philosophy, stressing that China's development must be for the people and by the people, and its fruits shared among the people.
The notion was highlighted again in the CPC Central Committee's proposals for formulating the 14th Five-Year Plan (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035, which called for efforts to promote common prosperity for everyone.
China, in recent years, has been striving to build a moderately prosperous society in all respects and pursuing more balanced development. The CPC members have played leading roles in a nationwide poverty alleviation campaign to make sure nobody is left behind.
Over the past eight years, more than three million public sector officials were sent from cities and towns to villages to fight against poverty on the front lines and over 1,800 people died during the fight, Xi said on Thursday after announcing the country's "complete victory" in eradicating absolute poverty.
Putting people's life and health first, China has taken strict measures to battle the COVID-19 pandemic and effectively contained the virus, thanks to people from all walks of life for their efforts and sacrifices, particularly the CPC members.
More than 39 million CPC members fought the virus at the front line, and more than 13 million volunteered their services. Nearly 400 CPC members have defended others' lives and safety at the cost of their own.
When many parts of the country grappled with severe floods last summer, the Organization Department of the CPC Central Committee issued a circular to call on primary-level CPC organizations and members to fully play their role in flood control and relief work, urging them to ensure the safety of people's lives and property.
As China embarks on a new journey to fully build a modern socialist country, today's Chinese Communists – putting the people's and the nation's interests above those of themselves – are gearing up to take on their responsibilities as the older generations did.
Original article: https://news.cgtn.com/news/2021-02-27/What-are-generations-of-Chinese-Communists-striving-for--YdM2IOWzO8/index.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210227005021/en/
Contact information
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
